Neuralstem (CUR) Shares Gap Up to $2.09
Neuralstem, Inc. (NASDAQ:CUR) shares gapped up prior to trading on Friday . The stock had previously closed at $2.03, but opened at $2.09. Neuralstem shares last traded at $2.14, with a volume of 3215000 shares changing hands.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. National Asset Management Inc. increased its stake in shares of Neuralstem by 9.2% during the second quarter. National Asset Management Inc. now owns 22,985 shares of the company’s stock worth $134,000 after purchasing an additional 1,937 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Neuralstem by 1.1% during the second quarter. Vanguard Group Inc. now owns 345,346 shares of the company’s stock worth $2,000,000 after purchasing an additional 3,853 shares in the last quarter. Blair William & Co. IL increased its stake in shares of Neuralstem by 171.0% during the second quarter. Blair William & Co. IL now owns 87,343 shares of the company’s stock worth $506,000 after purchasing an additional 55,115 shares in the last quarter. Finally, Alethea Capital Management LLC increased its stake in shares of Neuralstem by 100.0% during the second quarter. Alethea Capital Management LLC now owns 328,788 shares of the company’s stock worth $1,904,000 after purchasing an additional 164,394 shares in the last quarter. 7.14% of the stock is owned by institutional investors.
WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.watchlistnews.com/neuralstem-cur-shares-gap-up-to-2-09/1769103.html.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.